Exploring Add-on Therapy With CK0804 for Patients With Myelofibrosis With Suboptimal Response to Ruxolitinib
In a preliminary analysis of a phase 1 trial, CXCR4-enriched T regulatory cell therapy (CK0804) as an addition to ruxolitinib treatment demonstrated initial safety and promising clinical activity for patients with myelofibrosis receiving ruxolitinib who have palpable splenomegaly, symptoms, or grade 2 cytopenia.
These results were presented by Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, Texas, at the 66th ASH Annual Meeting in San Diego, California.
Investigators explored this option due to research that suggested deregulated inflammatory pathways might contribute to suboptimal therapeutic efficacy of ruxolitinib for patients with myelofibrosis. In preclinical studies, cord blood-derived, CXCR4-enriched T regulatory cells showed ability to suppress inflammatory cytokines.
“This preliminary analysis of run-in phase of study evaluating CXCR4-enriched T [regulatory] cell therapy as addition to ruxolitinib shows initial safety with no myelosuppressive adverse events and promising clinical activity,” concluded Masarova and colleagues.
Source:
Masarova L, Huang M, Goel S, et al. A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib. Dec 7-10, 2024; San Diego, CA. Abstract: 999
